

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
01 May 2025 (01.05.2025)



(10) International Publication Number
WO 2025/090850 A1

(51) International Patent Classification:

A61K 39/00 (2006.01) C07K 7/06 (2006.01)
C07K 14/705 (2006.01) C12N 15/85 (2006.01)
A61K 38/17 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/US2024/052934

(22) International Filing Date:

25 October 2024 (25.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/546,105 27 October 2023 (27.10.2023) US
63/554,734 16 February 2024 (16.02.2024) US

(71) Applicant: **TSCAN THERAPEUTICS, INC.** [US/US];
830 Winter Street, Waltham, MA 02451 (US).

(72) Inventors: **NABILSI, Nancy**; c/o Tscan Therapeutics, Inc.,
830 Winter Street, Waltham, MA 02451 (US). **TADROS,
Jenny**; c/o Tscan Therapeutics, Inc., 830 Winter Street,
Waltham, MA 02451 (US). **JUREWICZ, Mollie, M.**; c/o
Tscan Therapeutics, Inc., 830 Winter Street, Waltham, MA
02451 (US). **MACBEATH, Gavin**; c/o Tscan Therapeutics,
Inc., 830 Winter Street, Waltham, MA 02451 (US).

(74) Agent: **CHOI, Philip, S.** et al.; Foley Hoag LLP, 155 Sea-
port Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEP-
TIDES, AND USES THEREOF

Figure 2B



(57) Abstract: Provided herein are MAGEA1 immunogenic peptides, binding proteins recognizing MAGEA1 immunogenic peptides, and uses thereof.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*